Addressing Barriers to Access and Improving Equity in Biomarker Testing



Foster Education


Improve Timing


Addressing Barriers


Sound Bites



The use of biomarker testing and targeted therapies has become a standard of care for NSCLC. However, not all patients benefit equally from these advances and there remain notable racial, ethnic, and socioeconomic disparities related to access and utilization of these advancements in care.1 There is a need for improved strategies to address disparities and barriers related to access and use of guideline-indicated biomarker testing and targeted therapy in order to improve cancer-related outcomes in these patient populations.


  1. Health equity in biomarker testing and targeted therapy. American Cancer Society, 2022. Accessed March 20, 2023. https://www.fightcancer.org/sites/default/files/health_equity_in_biomarker_testing_and_targeted_therapy_.pdf

© 2023 MJH Life Sciences®. Content developed independently by OncLive®.